Structural changes from wild-type define tumor-rejecting neoantigens

Given the paucity of shared mutations, this work supports the need for personalized neoantigen vaccines in cSCC. To facilitate further discovery, we provide a clinically relevant mouse cSCC model with two defined neoantigens that mediate tumor rejection. Structural changes in the exposure of features that promote T cell receptor recognition defined tumor-rejecting neoantigens. Incorporation of structural modeling to predict changes in T cell receptor accessibility is anticipated to improve the selection of neoantigens for inclusion in personalized cancer vaccines.

Authors

Institutions

Publication Details

Journal
Journal for ImmunoTherapy of Cancer
Published
2025-10-01
DOI
https://doi.org/10.1136/jitc-2025-013148
Primary Topic
Immunotherapy and Immune Responses
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Structural changes from wild-type define tumor-rejecting neoantigens

Anngela C. Adams, Lauren M Herrmann, Kenneth H. Buetow, Denise J. Roe et al.
Journal for ImmunoTherapy of Cancer
Immunotherapy and Immune Responses
article

Structural changes from wild-type define tumor-rejecting neoantigens

Anngela C. Adams, Lauren M Herrmann, Kenneth H. Buetow, Denise J. Roe, Janko Nikolich‐Žugich, Elizabeth S. Borden, Chad A. Brambley, Sandip Ashok Sonar, Alysia Hughes, Anne M. Macy, Aaron R. Mangold, Karen Taraszka Hastings, Brian M. Baker, Xing Li, Tao Ma, Melissa Wilson
article en

Abstract

Given the paucity of shared mutations, this work supports the need for personalized neoantigen vaccines in cSCC. To facilitate further discovery, we provide a clinically relevant mouse cSCC model with two defined neoantigens that mediate tumor rejection. Structural changes in the exposure of features that promote T cell receptor recognition defined tumor-rejecting neoantigens. Incorporation of structural modeling to predict changes in T cell receptor accessibility is anticipated to improve the selection of neoantigens for inclusion in personalized cancer vaccines.

Journal for ImmunoTherapy of CancerVol. 13(10)
University of Notre Dame (US), University of Arizona (US), University of Phoenix (US), Phoenix VA Health Care System (US), Mayo Clinic in Arizona (US), Mayo Clinic in Florida (US), University of Arizona Cancer Center, Phoenix College (US), Arizona State University (US)
U.S. Department of Veterans Affairs, American Skin Association, Arizona State University, University of Arizona, National Institutes of Health
Openalex Percentile: Top 69%
Immunotherapy and Immune Responses
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.